On May 8th, 2020, Pluristem announced that the U.S. Food and Drug Administration (FDA) has approved their PLX cell therapy as an Investigational New Drug (IND) for a Phase II clinical trial in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS). The study will be a randomized, double-blind, placebo-controlled, parallel-group …
Continue Reading